Holger Eidtmann - Concepedia

Author

Holger Eidtmann

German Breast group

Also Known As

A. Armour, B. Conrad, Eidtmann, H., Eidtmann, Holger, H Eidtmann, H. Eidtmann, Holger Eidtmann, M. Untch

244

Publications

23.6K

Citations

H-Index

Concepts

All Affiliations

German Breast group Helios Hospital Berlin-Buch Universitäts Frauenklinik Sana Klinikum Offenbach Goethe University Frankfurt

About

Holger Eidtmann is an author at German Breast group specializing in oncology, medicine, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	39	66	8.9K
2	Health Sciences	13	13	682
3	Cell Biology	4	4	162
4	Public Health	2	2	94
5	Biostatistics	1	1	244

Holger Eidtmann

Publications

18.6K

Citations

H-Index

Page 1

	Year	Citations
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes Gϋnter von Minckwitz, Michael Untch, Jens‐Uwe Blohmer, Journal of Clinical Oncology	2012	2.6K
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial José Baselga, Ian Bradbury, Holger Eidtmann, The Lancet Breast OncologyOncologyPathologyBreast CancerCancer Treatment	2012	1.3K
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer Michael Gnant, Brigitte Mlineritsch, Walter Schippinger, New England Journal of Medicine	2009	1K
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial Gϋnter von Minckwitz, Andreas Schneeweiß, Sibylle Loibl, The Lancet Oncology Gbg 66Breast OncologyMedicineRandomised Phase 2Neoadjuvant Carboplatin	2014	1K
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab Roberto Salgado, Carsten Denkert, Christine Campbell, JAMA Oncology	2015	589
Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study Michael Untch, Mahdi Rezai, Sibylle Loibl, Journal of Clinical Oncology Surgical OncologyOncologyHigh Pcr RateBreast OncologyImmunology	2010	550
Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer Gϋnter von Minckwitz, Holger Eidtmann, Mahdi Rezai, New England Journal of Medicine	2012	528
Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial Sabine Riethdorf, Volkmar Müller, Liling Zhang, Clinical Cancer Research	2010	487
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial Michael Gnant, Brigitte Mlineritsch, Herbert Stoeger, The Lancet Oncology Zoledronic AcidBreast OncologyOncologyEndocrine-related CancerEndocrine Oncology	2011	462
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial Michael Untch, Sibylle Loibl, Joachim Bischoff, The Lancet Oncology Gbg 44MedicineRandomised Phase 3Metronomic TherapyPathology	2012	453

Page 1